<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Dawson H</dc:creator>
  <dc:creator>Galuppini F</dc:creator>
  <dc:creator>Träger P</dc:creator>
  <dc:creator>Berger MD</dc:creator>
  <dc:creator>Studer P</dc:creator>
  <dc:creator>Brügger L</dc:creator>
  <dc:creator>Zlobec I</dc:creator>
  <dc:creator>Inderbitzin D</dc:creator>
  <dc:creator>Lugli A</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Tumor budding is a robust prognostic parameter in colorectal cancer and can be used as an additional factor to guide patient management. Although backed by large bodies of data, a standardized scoring method is essential for integrating tumor budding in reporting protocols. The International Tumor Budding Consensus Conference (ITBCC) 2016 has proposed such a scoring system. The aim of this study is to validate the ITBCC method of tumor budding assessment on a well-characterized colorectal cancer cohort. Three hundred seventy-nine patients with resected stage I-IV colorectal cancer were entered into the study. Tumor budding was scored by 2 pathologists according to the ITBCC recommendations on hematoxylin and eosin-stained slides and scored as BD1 (low grade), BD2 (intermediate grade), and BD3 (high grade). Analysis was performed using a 3-tier approach, a 2-tier approach (BD1 + 2 versus BD3) and budding as a continuous variable. High-grade tumor budding was associated with adverse clinicopathological features including higher pT, higher pN stage, and higher TNM stage (all P &lt; .001) and poorer overall survival on univariate analysis (P = .0251 for BD1/2/3, P = .0106 for BD1 + 2 versus BD3, and P = .0195 for continuous scores; hazard ratio, 1.023 [95% confidence interval, 1.004-1.043 per bud]). In stage II cancers, BD3 was associated with poorer disease-free survival (P &lt; .01). Tumor budding assessed by the method proposed by the ITBCC is applicable to colorectal cancer resection specimens and can be used for widespread reporting in routine.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/169886</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.humpath.2018.10.023</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30428391</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Human pathology. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Colorectal cancer</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Consensus conference</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Prognostic factor</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Tumor budding</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Validation study</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Adenocarcinoma</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Colorectal Neoplasms</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Disease-Free Survival</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Neoplasm Staging</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Prognosis</dc:subject>
  <dc:title xmlns:ns15="xml" ns15:lang="en">Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>